Login to Your Account

FDA Urged to Keep Distinctions Between Biologics and Copies

By Mari Serebrov
Washington Editor

Tuesday, June 18, 2013
Biologics are innovative drugs, biosimilars are copies, and never the twain shall meet. That's the underlying message brand drugmakers sent to the FDA as they urged it to maintain the distinctions between the 351(a) and 351(k) approval paths.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription